TY - JOUR
T1 - DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression
AU - Ziv, Etay
AU - Rice, Samuel L.
AU - Filtes, John
AU - Yarmohammadi, Hooman
AU - Boas, F. Edward
AU - Erinjeri, Joseph P.
AU - Petre, Elena Nadia
AU - Brody, Lynn A.
AU - Brown, Karen T.
AU - Covey, Anne M.
AU - Getrajdman, George I.
AU - Maybody, Majid
AU - Raj, Nitya
AU - Sofocleous, Constantinos T.
AU - Solomon, Stephen B.
AU - Reidy-Lagunes, Diane
N1 - Funding Information:
This work was partially funded by a Society of Interventional Radiology Pilot Grant, a North American Neuroendocrine Tumor Society grant, and Cancer Center Support Grant 2P30CA008748-48 .
Funding Information:
This work was partially funded by a Society of Interventional Radiology Pilot Grant, a North American Neuroendocrine Tumor Society grant, and Cancer Center Support Grant 2P30CA008748-48.
Publisher Copyright:
© 2018 SIR
PY - 2018/11
Y1 - 2018/11
N2 - Purpose: To identify common gene mutations in patients with neuroendocrine liver metastases (NLM) undergoing transarterial embolization (TAE) and establish relationship between these mutations and response to TAE. Materials and Methods: Patients (n = 51; mean age 61 y; 29 men, 22 women) with NLMs who underwent TAE and had available mutation analysis were identified. Mutation status and clinical variables were recorded and evaluated in relation to hepatic progression-free survival (HPFS) (Cox proportional hazards) and time to hepatic progression (TTHP) (competing risk proportional hazards). Subgroup analysis of patients with pancreatic NLM was performed using Fisher exact test to identify correlation between mutation and event (hepatic progression or death) by 6 months. Changes in mutation status over time and across specimens in a subset of patients were recorded. Results: Technical success of TAE was 100%. Common mutations identified were MEN1 (16/51; 31%) and DAXX (13/51; 25%). Median overall survival was 48.7 months. DAXX mutation status (hazard ratio = 6.21; 95% confidence interval [CI], 2.67–14.48; P <.001) and tumor grade (hazard ratio = 3.05; 95% CI, 1.80–5.17; P <.001) were associated with shorter HPFS and TTHP on univariate and multivariate analysis. Median HPFS was 3.6 months (95% CI, 1.7–5.3) for patients with DAXX mutation compared with 8.9 months (95% CI, 6.6–11.4) for patients with DAXX wild-type status. In patients with pancreatic NLMs, DAXX mutation status was associated with hepatic progression or death by 6 months (P =.024). DAXX mutation status was concordant between primary and metastatic sites. Conclusions: DAXX mutation is common in patients with pancreatic NLMs. DAXX mutation status is associated with shorter HPFS and TTHP after TAE.
AB - Purpose: To identify common gene mutations in patients with neuroendocrine liver metastases (NLM) undergoing transarterial embolization (TAE) and establish relationship between these mutations and response to TAE. Materials and Methods: Patients (n = 51; mean age 61 y; 29 men, 22 women) with NLMs who underwent TAE and had available mutation analysis were identified. Mutation status and clinical variables were recorded and evaluated in relation to hepatic progression-free survival (HPFS) (Cox proportional hazards) and time to hepatic progression (TTHP) (competing risk proportional hazards). Subgroup analysis of patients with pancreatic NLM was performed using Fisher exact test to identify correlation between mutation and event (hepatic progression or death) by 6 months. Changes in mutation status over time and across specimens in a subset of patients were recorded. Results: Technical success of TAE was 100%. Common mutations identified were MEN1 (16/51; 31%) and DAXX (13/51; 25%). Median overall survival was 48.7 months. DAXX mutation status (hazard ratio = 6.21; 95% confidence interval [CI], 2.67–14.48; P <.001) and tumor grade (hazard ratio = 3.05; 95% CI, 1.80–5.17; P <.001) were associated with shorter HPFS and TTHP on univariate and multivariate analysis. Median HPFS was 3.6 months (95% CI, 1.7–5.3) for patients with DAXX mutation compared with 8.9 months (95% CI, 6.6–11.4) for patients with DAXX wild-type status. In patients with pancreatic NLMs, DAXX mutation status was associated with hepatic progression or death by 6 months (P =.024). DAXX mutation status was concordant between primary and metastatic sites. Conclusions: DAXX mutation is common in patients with pancreatic NLMs. DAXX mutation status is associated with shorter HPFS and TTHP after TAE.
UR - http://www.scopus.com/inward/record.url?scp=85055021340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055021340&partnerID=8YFLogxK
U2 - 10.1016/j.jvir.2018.05.023
DO - 10.1016/j.jvir.2018.05.023
M3 - Article
C2 - 30342802
AN - SCOPUS:85055021340
SN - 1051-0443
VL - 29
SP - 1519
EP - 1526
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
IS - 11
ER -